NICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913

Riesco Martinez, M. C.Capdevila, J.Alonso, V.Teule, A.Grande, E.Jimenez-Fonseca, P.Benavent, M.Alonso Gordoa, T.Custodio, A.Hierro Carbo, C.Lopez, C.Sevilla Garcia, I.Garcia-Carbonero, R.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/26986enNICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913conference outputopen access10.1016/j.annonc.2020.08.20921569-8041http://www.annalsofoncology.org/article/S0923753420420897/pdf573469101475